AI English summary of an SEC filing — figures as filed
Edwards Lifesciences EWThe company said net sales for 2023 were $6.0 billion, up $622.4 million from 2022, driven by growth in TAVR product sales.
Key points
AI summaryThe company said net sales for 2023 were $6.0 billion, up $622.4 million from 2022, driven by growth in TAVR product sales.
Edwards Lifesciences said the decline in net income and diluted earnings per share in 2023 was driven primarily by an after-tax charge of $134.9 million related to an intellectual property agreement. It entered into the agreement with Medtronic on April 12, 2023 and recognized a charge of $37.0 million in March and $139.0 million in April.
The company said operating cash flow for 2023 was $895.8 million, a decrease of $322.4 million from 2022, citing a $300.0 million payment under the Intellectual Property Agreement with Medtronic as the main factor. The company also said it repurchased 11.3 million shares for a total of $867.1 million in the same year.
The company said the additional tax the IRS is seeking above its filing position for the 2015 through 2017 tax years is $269.3 million before interest and a repatriation tax offset. It plans to contest the matter through the judicial process and to make an additional deposit of $200 million to $300 million with the IRS by Q2 2024.
Key figures
Fiscal year ended December 31, 2023
- Revenue
- $6.0B
- Operating income
- $1.5B
- Net income
- $1.4B
- EPS
- $2.30
- Gross profit
- $4.6B
- Operating cash flow
- $896M
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
2023 Net Sales $6.0 billion, TAVR Sales Growth
The company said net sales for 2023 were $6.0 billion, up $622.4 million from 2022, driven by growth in TAVR product sales.
Source · Based on the MD&A text of the filing
Medtronic Intellectual Property Agreement and After-Tax Charge of $134.9 million
Edwards Lifesciences said the decline in net income and diluted earnings per share in 2023 was driven primarily by an after-tax charge of $134.9 million related to an intellectual property agreement. It entered into the agreement with Medtronic on April 12, 2023 and recognized a charge of $37.0 million in March and $139.0 million in April.
Source · Based on the MD&A text of the filing
2023 Operating Cash Flow $895.8 million, Share Repurchases $867.1 million
The company said operating cash flow for 2023 was $895.8 million, a decrease of $322.4 million from 2022, citing a $300.0 million payment under the Intellectual Property Agreement with Medtronic as the main factor. The company also said it repurchased 11.3 million shares for a total of $867.1 million in the same year.
Source · Based on the MD&A text of the filing
IRS Notice of Deficiency of $269.3 million and Planned Deposit
The company said the additional tax the IRS is seeking above its filing position for the 2015 through 2017 tax years is $269.3 million before interest and a repatriation tax offset. It plans to contest the matter through the judicial process and to make an additional deposit of $200 million to $300 million with the IRS by Q2 2024.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…